News

This is the first FDA approval of a systemic treatment for alopecia areata, which is estimated to affect 300,000 patients in the US.

Although a small proportion of patients from both the US and Korean centers experienced new onset facial dermatitis, investigators suggested steroid withdrawal should be considered when diagnosing erythema in patients.

Investigators note that MMP2 expression was significantly decreased in TTP-treated patients with photodamage.

Dr. Auriemma examines recent paradigm shifts in obesity care, from new pharmacotherapy options to the important role of stakeholders in reducing rates.

Smoking was not linked to colonic transit times and colonic transit was not associated with IBS symptom severity.

The study popuation had a higher visual acuity at 12 months, despite receiving fewer aflibercept injections.

Among the factors associated with psoriasis, the location of some patients from this large, Italian cohort was considered to be the most influential.

Though previous research had demonstrated an increased risk of MetS in patients with psoriasis, this study was first to consider the prevalence of the condition a global scale.

Data show myopic children experienced higher scores of depression than normally-sighted children.

Some of the favorable responses to voxelotor treatment and signs of hematologic response after voxelotor treatment included increased Hb levels, decreased reticulocyte percentage, and decreased total bilirubin.

A team of investigators observe notably improved health care cost savings among patients who initiated care more than a year prior to those who haven't at all.

While there's evidence that blue light exposure can impact an individual's circadian system, Dr. Aric Prather explains that technology is only one factor of the complex issue.

In the fourth and final episode from ADA 2022, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, take a deep dive into the meeting from their perspectives as a clinical pharmacy specialist and a nurse practitioner, including their picks for the most exciting advances in diabetes technology to come from the year’s largest diabetes meeting.

Dr. Amy Licis details recent observations regarding potential underlying neurobiological reasons for sleep disturbance in pediatric patients with ADHD or autism.

The HTRA1 and CFH risk alleles, family history of AMD, the LOC387715 risk allele, and cardiovascular disease were all linked to an increased risk of AMD.

Intravenous opioid use for VOC decreased by 52% in inpatient services between 2017-2018, while oral opioid use increased.

C1M, C3M, and C4M were significantly reduced in patients with structuring disease.

In the third special edition episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives from ADA 2022, Jasmine Gonzalvo, PharmD, joins hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss prevailing barriers in diabetes management, including access to new pharmacologic agents as well as newer diabetes technologies.

Dr. Karan Lal returns to discuss key identifiers of pediatric morphea, and how dermatologists can collaborate with doctors from different branches of medicine to treat the disease.

Currently many more patients undergo right heart catheterization than is necessary for diagnosing pulmonary hypertension in patients with systemic sclerosis.

Dr. Smith provides an overview of this rare group of diseases, its variations, and where to find additional support outside of clinical environments.

Dr. Lisa Arkin speaks to how evidence-based, expert opinion-led consensus treatment plans for scleroderma can help change the way patients and providers approach the disease.

Dr. Cordoro speaks on the prevalence of variants of scleroderma in children, and how provides can better recognize and treat the disease in pediatric populations.

In the latest edition of Don’t Miss a Beat, hosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, are joined by special guest Anjali Owens, MD. An assistant professor of medicine and medical director of the Center for Inherited Cardiac Disease at the Perelman School of Medicine, Owens takes our hosts on a deep dive into the current state of management for oHCM and the impact of the US FDA's approval of mavacamten.

Investigators suggested that additional studies could explore the rate of mental health services use in patients with scleroderma with a clinical diagnosis of major depressive disorder or other mental health disorders.

The data obtained from the study supported the idea that IL-6 could be used as a potential marker for judging the efficacy of SSc.

Despite this, investigators suggested better quality filtering of scleroderma content on YouTube.

There is a growing body of evidence showing the value of rituximab in the treatment of SSc-ILD.